Information Provided By:
Fly News Breaks for August 27, 2015
BSX
Aug 27, 2015 | 06:12 EDT
Goldman upgraded Boston Scientific to Buy from Neutral with a $20 price target citing recent weakness in shares. The firm's bullish thesis is based on accelerating organic top-line growth, synergies from the American Medical Systems transaction and underlying mix improvements, and strong free cash flow and EBITDA growth.
News For BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.